Yang Zhou

Yang Zhou

Auto-generated profile, based on publicly available information

Yang Zhou

Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in Science Advances
Verified
Journal Article
Open access
YZYang Zhou
Yang Zhou
YDYekun Deng
Yekun Deng
ZLZhongmin Liu
Zhongmin Liu
MYMengyuan Yin
Mengyuan Yin
MHMengying Hou
Mengying Hou
LYLichen Yin
Lichen Yin
Biomimetic nanodecoys reconstruct the osteoclast/osteoblast balance to treat postmenopausal osteoporosis.

11 July 2025 in Science Advances
Verified
Journal Article
Open access
DCDesheng Cao
Desheng Cao
JZJunliang Zhu
Junliang Zhu
YGYang Guo
Yang Guo
YZYang Zhou
Yang Zhou
JZJia Zeng
Jia Zeng
LYLichen Yin
Lichen Yin
As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A 4 B 3 C 7 was formulated into LNP-A 4 B 3 C 7 with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H 2 O 2 -triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A 4 B 3 C 7 after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.

7 March 2025 in Acta Biomaterialia
Verified
Journal Article
Closed access
FWFan Wu
Fan Wu
YQYu Qian
Yu Qian
CGChenglong Ge
Chenglong Ge
YZYang Zhou
Yang Zhou
JYJing Yan
Jing Yan
SDShanzhou Duan
Shanzhou Duan

30 April 2026 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
XLXiaohui Li
Xiaohui Li
SDShanzhou Duan
Shanzhou Duan
JYJiandong Yang
Jiandong Yang
CPChunxian Piao
Chunxian Piao
YZYang Zhou
Yang Zhou
YCYongbing Chen
Yongbing Chen
Pulmonary delivery of anti-inflammatory siRNA holds great potential for the management of severe pneumonia. However, conventional siRNA carriers, primarily cationic polymers, struggle to penetrate the mucus barrier, resulting in limited transfection efficiency. Herein, nanocomplexes (NCs) capable of penetrating both the mucus and cytomembrane barriers were developed to deliver TNF-α siRNA (siTNF-α) for effective pneumonia management. To construct the NCs, membrane-penetrating polypeptide (DPP) first condensed siTNF-α and formed a cationic inner core, which was further coated with a charge-reversal polymer (PD) followed by the adsorption of a RAGE-binding peptide (RBP) via electrostatic interactions. The resulting RDDsT NCs exhibited negatively charged surfaces and thus enabled efficient mucus layer penetration after intratracheal administration in lipopolysaccharide (LPS)-induced acute lung injury (ALI) mice. In the slightly acidic microenvironment of inflamed alveolar space, PD underwent charge reversal from negatively charged to positively charged, shedding off to facilitate the intracellular delivery of the DPP/siTNF-α core into alveolar macrophages. Meanwhile, the liberated RBP blocked RAGE–ligand interactions, further down-regulating pro-inflammatory factors. Consequently, the cooperative action of siTNF-α and RBP alleviated inflammation and propelled the recovery of pulmonary functions. This study renders an enlightened strategy to overcome the mucus/cytomembrane barrier against pulmonary siRNA delivery, and holds profound potential for gene/peptide co-therapy against pneumonia.


15 May 2026 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
LWLei Wu
Lei Wu
YWYehan Wang
Yehan Wang
KCKaimin Cai
Kaimin Cai
YZYang Zhou
Yang Zhou
YWYong Wang
Yong Wang
LYLichen Yin
Lichen Yin
Light-programmable, high-drug-loading PEG-PLA nanoparticles were developed to co-encapsulate both the photosensitizer (Ce6) and the hypoxia-activatable dimeric camptothecin prodrug (hQ-CPT 2 ) for synergistic antitumor treatment.